BioCryst Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the company's new drug application for ORLADEYO® (berotralstat) oral granules. This extension pertains to the use of the medication in pediatric patients aged 2 to 11 years with hereditary angioedema $(HAE)$. The FDA's decision to extend the deadline by three months, now set for December 12, 2025, follows the submission of additional final reports and formulation data by BioCryst, which were deemed a major amendment to the application. This extension allows the FDA ample time to conduct a thorough review of the new information.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.